title: Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis.
abstract: OBJECTIVE
  Despite a paucity of published supporting data, 5-aminosalicylate (5-ASA) use in pediatric ulcerative colitis (UC) is common. The present study describes the use and outcome of a large multicenter inception cohort of children with UC treated with 5-ASA.
  
  
  METHODS
  Data were obtained from the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry, a prospective North American observational study of children newly diagnosed as having inflammatory bowel disease ages 16 years or younger. Patient data are recorded at diagnosis, 30 days, and then quarterly. Patients are managed by physician dictate, not protocol. Disease activity is classified by physician global assessment. The primary outcome examined was corticosteroid (CS) free, inactive UC at 1 year following initiation of 5-ASA within 30 days of diagnosis (with or without concomitant CS use) without the need for rescue therapy (immunomodulators, biologics, or colectomy).
  
  
  RESULTS
  Study subjects included 213 patients newly diagnosed as having UC who received oral 5-ASA compounds (115 of whom also received CS) during the first 30 days after diagnosis, and no other oral therapies for the treatment of UC. Of these 213 patients, 86 (40%) were CS free and physician global assessment inactive at 1 year without rescue. Outcome was not associated with disease severity at diagnosis, demographic or laboratory factors examined, or initial dose of 5-ASA used.
  
  
  CONCLUSIONS
  Forty percent of children taking 5-ASA as primary maintenance therapy at diagnosis are in CS-free remission after 1 year of treatment. Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes.
authors: Connecticut Children's Medical Center, Hartford, CT 06106, USA. bzeisler@ccmckids.org
authors: Bella
authors: B
authors: Zeisler
authors: Trudy
authors: T
authors: Lerer
authors: James
authors: J
authors: Markowitz
authors: David
authors: D
authors: Mack
authors: Anne
authors: A
authors: Griffiths
authors: Athos
authors: A
authors: Bousvaros
authors: David
authors: D
authors: Keljo
authors: Joel
authors: J
authors: Rosh
authors: Jonathan
authors: J
authors: Evans
authors: Michael
authors: M
authors: Kappelman
authors: Anthony
authors: A
authors: Otley
authors: Marsha
authors: M
authors: Kay
authors: Andrew
authors: A
authors: Grossman
authors: Shehzad
authors: S
authors: Saeed
authors: Ryan
authors: R
authors: Carvalho
authors: Maria
authors: M
authors: Oliva-Hemker
authors: William
authors: W
authors: Faubion
authors: Boris
authors: B
authors: Sudel
authors: Marian
authors: M
authors: Pfefferkorn
authors: Farhat
authors: F
authors: Ashai-Khan
authors: Neal
authors: N
authors: Leleiko
authors: Jeffrey
authors: J
authors: Hyams
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002648:Child; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use*; D011446:Prospective Studies; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine